[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Ahmed Karam Helmy\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":42},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":21,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":26,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":41},"100617626","use-of-immune-checkpoint-inhibitors-in-patients-with-advanced-hepatocellular-carcinoma--efficacy-and-outcomes-100617626",false,"NCT07321067","Use of Immune Checkpoint Inhibitors in Patients With Advanced Hepatocellular Carcinoma : Efficacy and Outcomes","ICIs","Inclusion Criteria:\n\n* Adults (≥18 years) with radiologically or histologically confirmed advanced HCC\n* Candidates for systemic immune checkpoint inhibitors (e.g., atezolizumab-bevacizumab, durvalumab-tremelimumab).\n* Patients with preserved liver function. ( up to G2 using ALBI score or up to B (7 ) using Child-Pugh socring system) .\n\nExclusion Criteria:\n\n* Child-Pugh C liver function.\n* Prior liver transplantation.\n* patients with concurrent malignancies other than HCC.\n* Active autoimmune disease requiring systemic immunosuppression.","ALL","18 Years",{"count":19,"type":20},75,"ESTIMATED","12 Months","OBSERVATIONAL","the Objectives of this study are:\n\n• Primary Objective: To prospectively evaluate overall survival (OS), ICI-specific survival (OS-ICI), and progression-free survival (PFS) in patients with advanced HCC treated with immune checkpoint inhibitors.\n\nthe main question it aims to answer is: What are the clinical outcomes (overall survival, progression-free survival, and OS-ICIs) of immune checkpoint inhibitor therapy in patients with advanced hepatocellular carcinoma? Participants already taking immune checkpoint inhibitors as part of their regular medical care.",[25],"Advanced Hepatocellular Carcinoma (HCC)",[27,28],"advanced hepatocellular carcinoma","immune checkpoint inhibitors","NOT_YET_RECRUITING","2025-12-21",{"date":32,"type":33},"2026-01-06","ACTUAL",{"date":35,"type":20},"2026-01-01",{"date":37,"type":20},"2027-11-01",{"name":39,"class":40},"Ahmed Karam Helmy","OTHER",2,""]